FdaApplication
NDA 207318
Identifiers
- fda_app_no: NDA207318
Properties
| Property | Value |
|---|---|
| applicant_name | ACADIA PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2016-04-29 |
Revenue by product
NUPLAZID
| Period | Revenue |
|---|---|
| Q2 2026 | $183.1M |
| Q1 2026 | $166.9M |
| Q4 2025 | $174.4M |
| Q3 2025 | $177.5M |
| Q2 2025 | $168.5M |
| Q1 2025 | $159.7M |
| Q4 2024 | $162.9M |
| Q3 2024 | $159.2M |
| Q2 2024 | $157.4M |
| Q1 2024 | $129.9M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| NUPLAZID | PIMAVANSERIN TARTRATE | EQ 10MG BASE | TABLET;ORAL |
| NUPLAZID | PIMAVANSERIN TARTRATE | EQ 17MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET;ORAL |
2 products